While Genefill is popularly known for its unique body contouring solutions and their ability to volumize the buttocks, correct the concave deformities, and enhance the calves and hands. Not many are familiar with its other innovative offering, Genefill DX. It is a sterile resorbable gel-suspension of positively charged dextranomer microspheres in a hydrogel consisting of cross-linked hyaluronic acid sodium salt (Hylan Gel). The unique gel of Genefill Dx is designed to provide a 2-in-1 effect to the area with augmentation and onset of skin regeneration. The product supports the replacement of HA and encourages the process of neocollagenesis (Type 1 Collagen), ensuring increased fibroblast stimulation and collagen deposits for an overall regeneration of the dermal matrix and an overall healthy, youthful appearance. The highly viscose nature of the gel with increased stability against enzymes such as hyaluronidase also maximizes the results' duration. Genefill DX is an ideal solution for the effective treatment of skin defects such as prominent wrinkles, deep-set folds, and the recessed nature of cheeks, chin, and jawline.

What is Genefill DX?

Genefill DX is an absorbable skin implant with a high level of purity. It is a sterile, apyrogenic, visco-elastic, biologically compatible (non-immunizing, non-inflammatory, non-toxic) gel implant that is insoluble in water and produced from a hyaluronic acid gained through fermentation.

Genefill DX contains a sterile viscous gel consisting of a suspension of dextranomer microparticles and cross-linked hyaluronic acid of non-animal origin. It is a biocompatible and biodegradable implant for tissue augmentation.

The cross-linked hyaluronic acid serves mainly as a vehicle for the dextranomer microparticles. They stimulate the connective tissue at the locality of injection for a longer lasting result and naturally radiant look.

Composition

Every 1ml of Genefill DX is composed of 12 mg of cross-linked hyaluronic acid sodium salt, 50 mg of dextranomere, 6.9 mg of sodium chloride, and 1 ml of water injection. Both hyaluronic acid and dextranomer-microparticles of the products under discussion are biodegradable and biocompatible.

What makes Genefill DX Unique?

Like every Genefill product, Genefill Dx is also supported by the synergetic technologies of Advanced Thixotropic Technology and CRM technology. The former allows for stable and long-lasting results, while the latter enables excellent flowability in tissue for optimal dermal integration. In addition to these, the dextranomer as the key ingredient of Genefill Dx stimulates collagen production, ensuring even longer-lasting results.

Furthermore, Genefill Dx stands out as a unique product across the aesthetic landscape due to its Bio-Stimulation with positively charged microspheres and its unique combination of Hylan gel and dextranomers.

Application

The product is introduced to the injection site (subcutaneous tissue) by way of a dedicated sterile needle. It is explicitly injected in the intracutaneous and subcutaneous layers using the 25G needle to sculpt and define the face's form.

What is Dextranomer?

Dextran is a complex branched glucan (polysaccharide derived from the condensation of glucose). Dextrans are a "branched poly-α-d-glucosides of microbial origin having glycosidic bonds predominantly C-1 → C-6".

Dextranomer microspheres are composed of cross-linked dextran molecules with a positive surface charge. Dextranomer is a biodegradable glucose biopolymer and is hydrophilic.

Interestingly, dextranomer was initially developed for use in gel filtration chromatography. The medical-grade is a purified form that is sterilized*.

Dextran is synthesized from sucrose by certain lactic acid bacteria, the best-known being Leuconostoc mesenteroides and Streptococcus mutans.

Safety

Similar to the entire Genefill Line of dermal fillers, GeneFill DX is also CE Mark certified and produced only in ISO-verified state-of-the-art facilities based in Germany. Furthermore, Genefill Dx is also certified as medical device class III since 2009.

‍